Literature DB >> 28856708

Degeneration of serotonin neurons triggers spasticity in amyotrophic lateral sclerosis.

Hajer El Oussini1,2, Jelena Scekic-Zahirovic1,2, Pauline Vercruysse1,2,3, Christine Marques1,2, Sylvie Dirrig-Grosch1,2, Stéphane Dieterlé1,2, Gina Picchiarelli1,2, Jérôme Sinniger1,2, Caroline Rouaux1,2, Luc Dupuis1,2.   

Abstract

OBJECTIVE: Spasticity occurs in a wide range of neurological diseases, including neurodegenerative diseases, after trauma, and after stroke, and is characterized by increased reflexes leading to muscle hypertonia. Spasticity is a painful symptom and can severely restrict everyday life, but might also participate in maintaining a low level of motor function in severely impaired patients. Constitutive activity of the serotonin receptors 5-HT2B/C is required for the development of spasticity after spinal cord injury and during amyotrophic lateral sclerosis (ALS). We sought here to provide direct evidence for a role of brainstem serotonin neurons in spasticity.
METHODS: SOD1(G37R) mice expressing a conditional allele of an ALS-linked SOD1 mutation were crossed with Tph2-Cre mice expressing Cre in serotonergic neurons. Measurement of long-lasting reflex using electromyography, behavioral follow-up, and histological techniques was used to characterize spasticity and motor phenotype.
RESULTS: Deleting mutant SOD1 expression selectively in brainstem serotonin neurons was sufficient to rescue loss of TPH2 immunoreactivity and largely preserve serotonin innervation of motor neurons in the spinal cord. Furthermore, this abrogated constitutive activity of 5-HT2B/C receptors and abolished spasticity in end-stage mice. Consistent with spasticity mitigating motor symptoms, selective deletion worsened motor function and accelerated the onset of paralysis.
INTERPRETATION: Degeneration of serotonin neurons is necessary to trigger spasticity through the 5-HT2B/C receptor. The wide range of drugs targeting the serotonergic system could be useful to treat spasticity in neurological diseases. Ann Neurol 2017;82:444-456.
© 2017 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28856708     DOI: 10.1002/ana.25030

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  7 in total

Review 1.  Mechanisms of compensatory plasticity for respiratory motor neuron death.

Authors:  Yasin B Seven; Gordon S Mitchell
Journal:  Respir Physiol Neurobiol       Date:  2019-01-06       Impact factor: 1.931

2.  Genetic Analysis of Tryptophan Metabolism Genes in Sporadic Amyotrophic Lateral Sclerosis.

Authors:  Jennifer A Fifita; Sandrine Chan Moi Fat; Emily P McCann; Kelly L Williams; Natalie A Twine; Denis C Bauer; Dominic B Rowe; Roger Pamphlett; Matthew C Kiernan; Vanessa X Tan; Ian P Blair; Gilles J Guillemin
Journal:  Front Immunol       Date:  2021-06-14       Impact factor: 7.561

Review 3.  How Degeneration of Cells Surrounding Motoneurons Contributes to Amyotrophic Lateral Sclerosis.

Authors:  Roxane Crabé; Franck Aimond; Philippe Gosset; Frédérique Scamps; Cédric Raoul
Journal:  Cells       Date:  2020-11-27       Impact factor: 6.600

4.  Evaluation of a 5-HT2B receptor agonist in a murine model of amyotrophic lateral sclerosis.

Authors:  Laurent Monassier; Luc Dupuis; Alizée Arnoux; Estelle Ayme-Dietrich; Stéphane Dieterle; Marc-Antoine Goy; Stephan Schann; Mélanie Frauli
Journal:  Sci Rep       Date:  2021-12-08       Impact factor: 4.379

5.  Serotonergic Dysfunction in Amyotrophic Lateral Sclerosis and Parkinson's Disease: Similar Mechanisms, Dissimilar Outcomes.

Authors:  Yannick Vermeiren; Jana Janssens; Debby Van Dam; Peter P De Deyn
Journal:  Front Neurosci       Date:  2018-03-20       Impact factor: 4.677

Review 6.  Cortical Circuit Dysfunction as a Potential Driver of Amyotrophic Lateral Sclerosis.

Authors:  Aurore Brunet; Geoffrey Stuart-Lopez; Thibaut Burg; Jelena Scekic-Zahirovic; Caroline Rouaux
Journal:  Front Neurosci       Date:  2020-04-29       Impact factor: 4.677

7.  Semaphorin 7A restricts serotonergic innervation and ensures recovery after spinal cord injury.

Authors:  Kristina Loy; Julie Fourneau; Ning Meng; Carmen Denecke; Giuseppe Locatelli; Florence M Bareyre
Journal:  Cell Mol Life Sci       Date:  2020-10-30       Impact factor: 9.261

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.